{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:36:10Z","timestamp":1776371770748,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00280-019-03899-y","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T04:12:28Z","timestamp":1562559148000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetics of trabectedin in adolescent patients with cancer"],"prefix":"10.1007","volume":"84","author":[{"given":"Italo","family":"Poggesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Ouellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Hillewaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"Perez-Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"issue":"3","key":"3899_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1039\/b808331m","volume":"26","author":"C Cuevas","year":"2009","unstructured":"Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26(3):322\u2013337. https:\/\/doi.org\/10.1039\/b808331m","journal-title":"Nat Prod Rep"},{"issue":"8","key":"3899_CR2","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","volume":"9","author":"M D\u2019Incalci","year":"2010","unstructured":"D\u2019Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9(8):2157\u20132163. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0263","journal-title":"Mol Cancer Ther"},{"issue":"41","key":"3899_CR3","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1021\/bi960306b","volume":"35","author":"Y Pommier","year":"1996","unstructured":"Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35(41):13303\u201313309. https:\/\/doi.org\/10.1021\/bi960306b","journal-title":"Biochemistry"},{"issue":"2","key":"3899_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D\u2019Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2):249\u2013262. https:\/\/doi.org\/10.1016\/j.ccr.2013.01.008","journal-title":"Cancer Cell"},{"issue":"8","key":"3899_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786\u2013793. https:\/\/doi.org\/10.1200\/JCO.2015.62.4734","journal-title":"J Clin Oncol"},{"key":"3899_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1186\/s12885-015-1697-8","volume":"15","author":"J Khalifa","year":"2015","unstructured":"Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C (2015) Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer 15:700. https:\/\/doi.org\/10.1186\/s12885-015-1697-8","journal-title":"BMC Cancer"},{"issue":"16","key":"3899_CR7","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","volume":"48","author":"A Le Cesne","year":"2012","unstructured":"Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balana C, Schoffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD (2012) A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 48(16):3036\u20133044. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.012","journal-title":"Eur J Cancer"},{"key":"3899_CR8","unstructured":"Yondelis Prescribing Information. https:\/\/www.janssenmd.com\/pdf\/yondelis\/yondelis_pi.pdf . Accessed 27 Sep 2018"},{"issue":"1","key":"3899_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/157488409787236047","volume":"4","author":"JH Beumer","year":"2009","unstructured":"Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O (2009) Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Curr Clin Pharmacol 4(1):38\u201342","journal-title":"Curr Clin Pharmacol"},{"issue":"10","key":"3899_CR10","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.bcp.2009.02.020","volume":"77","author":"M Vermeir","year":"2009","unstructured":"Vermeir M, Hemeryck A, Cuyckens F, Francesch A, Bockx M, Van Houdt J, Steemans K, Mannens G, Aviles P, De Coster R (2009) In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 77(10):1642\u20131654. https:\/\/doi.org\/10.1016\/j.bcp.2009.02.020","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"3899_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10637-005-2902-4","volume":"23","author":"JH Beumer","year":"2005","unstructured":"Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH (2005) Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Investig New Drugs 23(5):429\u2013436. https:\/\/doi.org\/10.1007\/s10637-005-2902-4","journal-title":"Investig New Drugs"},{"issue":"10","key":"3899_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2165\/00003088-200746100-00005","volume":"46","author":"JJ Perez-Ruixo","year":"2007","unstructured":"Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS (2007) Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 46(10):867\u2013884","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3899_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/pbc.24201","volume":"59","author":"MK Chuk","year":"2012","unstructured":"Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E (2012) A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis(R), ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer 59(5):865\u2013869. https:\/\/doi.org\/10.1002\/pbc.24201","journal-title":"Pediatr Blood Cancer"},{"issue":"2 Pt 1","key":"3899_CR14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/1078-0432.672.11.2","volume":"11","author":"L Lau","year":"2005","unstructured":"Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S (2005) A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children\u2019s Oncology Group study. Clin Cancer Res 11(2 Pt 1):672\u2013677","journal-title":"Clin Cancer Res"},{"key":"3899_CR15","unstructured":"Food and Drug Administration. Clinical Pharmacology Review. NDA207953. https:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/DevelopmentResources\/UCM614989.pdf . Accessed 25 Sept 2018"},{"issue":"4","key":"3899_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2011.09.027","volume":"48","author":"S Baruchel","year":"2012","unstructured":"Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children\u2019s Oncology Group. Eur J Cancer 48(4):579\u2013585. https:\/\/doi.org\/10.1016\/j.ejca.2011.09.027","journal-title":"Eur J Cancer"},{"key":"3899_CR17","unstructured":"NONMEM Users Guides (1989\u20132011). Icon Development Solutions, Ellicott City"},{"key":"3899_CR18","unstructured":"R Development Core Team (2007) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. ISBN 3-900051-07-0. http:\/\/www.R-project.org"},{"issue":"1","key":"3899_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2125.2006.02584.x","volume":"62","author":"LD Ralph","year":"2006","unstructured":"Ralph LD, Sandstrom M, Twelves C, Dobbs NA, Thomson AH (2006) Assessment of the validity of a population pharmacokinetic model for epirubicin. Br J Clin Pharmacol 62(1):47\u201355. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02584.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3899_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171\u2013192","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"3899_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35(2):185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"3899_CR22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157\u20131167. https:\/\/doi.org\/10.1056\/NEJMra035092","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3899_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","volume":"67","author":"RF De Cock","year":"2011","unstructured":"De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5\u201316. https:\/\/doi.org\/10.1007\/s00228-009-0782-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3899_CR24","doi-asserted-by":"publisher","first-page":"E475","DOI":"10.1208\/aapsj070248","volume":"7","author":"B Meibohm","year":"2005","unstructured":"Meibohm B, Laer S, Panetta JC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475\u2013E487. https:\/\/doi.org\/10.1208\/aapsj070248","journal-title":"AAPS J"},{"issue":"11","key":"3899_CR25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1634\/theoncologist.2009-0160","volume":"14","author":"MS Merchant","year":"2009","unstructured":"Merchant MS, Mackall CL (2009) Current approach to pediatric soft tissue sarcomas. Oncologist 14(11):1139\u20131153. https:\/\/doi.org\/10.1634\/theoncologist.2009-0160","journal-title":"Oncologist"},{"issue":"12","key":"3899_CR26","first-page":"4725","volume":"6","author":"C van Kesteren","year":"2000","unstructured":"van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Math t RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH (2000) Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6(12):4725\u20134732","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3899_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03899-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T03:10:51Z","timestamp":1663902651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03899-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3899"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03899-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"IP is an employee of Janssen-Cilag, Italy; JJPR and VH are employees of Janssen Pharmaceutica NV, Belgium; DO and MG are employees of Janssen Research and Development, LLC, USA (parent company Johnson and Johnson). BV received fees from Janssen as a consultant on this analysis. EF was a government employee at the time of the clinical trial and is currently a faculty member at the Perelman School of Medicine at the University of Pennsylvania, she received no funding from Janssen Pharmaceutica or Johnson and Johnson for conduct of the clinical trial or preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}